Literature DB >> 11206466

Structure--activity relationships of side-chain modified didemnins.

X Ding1, M D Vera, B Liang, Y Zhao, M S Leonard, M M Joullié.   

Abstract

The synthesis and antitumor activity of a novel didemnin B analogue containing a psi[CH2NH] amide bond surrogate between N-Me-D-Leu7 and Pro8 are reported. The analogue shows activity (GI50 = 4 nM) comparable to that of didemnin B (GI50 = 13 nM) in the NCI-60 tumor cell screen. This result, along with new data from previously reported synthetic didemnin analogues, is discussed within the context of the side-chain SAR for didemnins.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11206466     DOI: 10.1016/s0960-894x(00)00638-7

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

Review 1.  The utility of metabolomics in natural product and biomarker characterization.

Authors:  Daniel G Cox; Joonseok Oh; Adam Keasling; Kim L Colson; Mark T Hamann
Journal:  Biochim Biophys Acta       Date:  2014-08-20

2.  Synthetic studies of tamandarin B side chain analogues.

Authors:  Kenneth M Lassen; Jisun Lee; Madeleine M Joullié
Journal:  J Org Chem       Date:  2010-05-07       Impact factor: 4.354

3.  Bacterial biosynthesis and maturation of the didemnin anti-cancer agents.

Authors:  Ying Xu; Roland D Kersten; Sang-Jip Nam; Liang Lu; Abdulaziz M Al-Suwailem; Huajun Zheng; William Fenical; Pieter C Dorrestein; Bradley S Moore; Pei-Yuan Qian
Journal:  J Am Chem Soc       Date:  2012-04-06       Impact factor: 15.419

4.  Establishment and characterisation of a human carcinoma cell line with acquired resistance to Aplidin.

Authors:  A Losada; J M López-Oliva; J M Sánchez-Puelles; L F García-Fernández
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.